Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | LPL | P06858 | 3/20 | 0.57 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28656641 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL5599017 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL19304390 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL2442972 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL9802185 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL2998787 | 0.98 | CYP1A2 (0.60) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| Nitrogen SCHEMBL23668052 | 0.96 | CYP1A2 (0.58) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL417687 | 0.92 | TAAR1 (0.59) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL19524669 | 0.90 | TAAR1 (0.65) | CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL27390155 | 0.90 | LPL (0.51) | CYP1A2CYP2D6CYP2C19LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0805672-B1 | METHODS, COMPOSITIONS, AND DENTAL DELIVERY SYSTEMS FOR THE PROTECTION OF THE SURFACES OF TEETH | HOMOLA ANDREW M (US) | 2004-08-25 | — | — | EP | claimed |
| CN-119907823-A | Polymer, film, composition, ink, electronic component, photoelectric conversion element, solar cell module, and image sensor | 住友化学株式会社 | 2025-04-29 | — | — | CN | disclosed |
| CN-118076663-A | Composition and ink composition | 住友化学株式会社 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024075536-A1 | POLYMER, FILM, COMPOSITION, INK, ELECTRONIC ELEMENT, PHOTOELECTRIC CONVERSION ELEMENT, SOLAR CELL MODULE, AND IMAGE SENSOR | 住友化学株式会社 | 2024-04-11 | — | — | WO | disclosed |
| WO-2024075537-A1 | REACTIVE COMPOUND, PRODUCTION METHOD FOR POLYMER COMPOUND, AND INTERMEDIATE | 住友化学株式会社 | 2024-04-11 | — | — | WO | disclosed |
| EP-3523308-B1 | ORGANIC SEMICONDUCTING COMPOUNDS | RAYNERGY TEK INC (TW) | 2023-09-06 | — | — | EP | disclosed |
| EP-3620458-B1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE COMPRISING SAME | LG CHEMICAL LTD (KR) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023058725-A1 | COMPOSITION AND INK COMPOSITION | 住友化学株式会社 | 2023-04-13 | — | — | WO | disclosed |
| WO-2023058724-A1 | COMPOSITION AND INK COMPOSITION | 住友化学株式会社 | 2023-04-13 | — | — | WO | disclosed |
| US-11401275-B2 | Non-fullerene based heterocyclic compound and organic electronic device including same | LG CHEM, LTD. (KR) | 2022-08-02 | — | — | US | disclosed |
| US-20110187266-A1 | POLYMER COMPOUND AND LIGHT EMITTING DEVICE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-04 | — | — | US | disclosed |
| US-20110127517-A1 | COMPOUND CONTAINING 1,3-DIENE STRUCTURE AND METHOD FOR PRODUCING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-06-02 | — | — | US | disclosed |
| US-20110127516-A1 | POLYMER COMPOUND AND LIGHT-EMITTING ELEMENT USING SAME | SUMITOMO CHEMICAL COMPANY ,LIMITED (JP) | 2011-06-02 | — | — | US | disclosed |
| EP-2311893-A1 | COMPOUND CONTAINING 1,3-DIENE STRUCTURE AND METHOD FOR PRODUCING SAME | Sumitomo Chemical Company, Limited (JP) | 2011-04-20 | — | — | EP | disclosed |
| EP-2308910-A1 | POLYMER COMPOUND AND LIGHT-EMITTING ELEMENT USING SAME | Sumitomo Chemical Company, Limited (JP) | 2011-04-13 | — | — | EP | disclosed |
| WO-1998043649-A2 | AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
| CN-1034864-C | Maillard reaction inhibitor | OTSUKA PHARMA CO LTD (JP) | 1997-05-14 | — | — | CN | disclosed |
| US-5422360-A | Hydrazonoimidazolidin-4-one derivatives; treatment of diabetes and aging disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-06 | — | — | US | disclosed |
| EP-0531812-A1 | Maillard reaction inhibitor, process for producing it, composition containing it and the use thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
| CN-1069728-A | Maillard reaction inhibitor | OTSUKA PHARMA CO LTD (JP) | 1993-03-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110127516-A1 | POLYMER COMPOUND AND LIGHT-EMITTING ELEMENT USING SAME | RER1, NAP1L1, CRY1 | CYP1A2 1455/4885CYP2D6 3653/4885CYP2C19 3339/4885 |
| US-20110127517-A1 | COMPOUND CONTAINING 1,3-DIENE STRUCTURE AND METHOD FOR PRODUCING SAME | KCNMA1, KCNA1, KCNJ11 | CYP1A2 867/4885CYP2D6 2609/4885CYP2C19 3323/4885 |
| US-11401275-B2 | Non-fullerene based heterocyclic compound and organic electronic device including same | EMC1, CYP1B1, CYP1A1 | CYP1A2 32/4885CYP2D6 300/4885CYP2C19 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.